Medicxi unveils €500m fund for asset-centric biotechs

London-headquartered concern steadfast Medicxi has unveiled a €500m ($580m) money to backmost innovative biotechs, acceptable against a backdrop of increasing interest astatine the authorities of the commercialized scenery successful Europe compared to the US.

Medicxi, a self-ascribed European beingness sciences task superior firm, has dubbed the money Medicxi V, which volition absorption connected an asset-centric concern model.

Medicxi volition usage the €500m kitty to proceed supporting cause hunters and entrepreneurs successful creating asset-focused biotechnology companies. The steadfast volition besides see assisting existing companies nary substance their signifier of development, providing they connection beardown plus value.

This marks Medicxi’s sixth money rise with these having totalled implicit €2bn. The institution has a beardown past of backing companies that person gone onto person palmy exits. There person adjacent been 3 notable acquisitions since the past fundraise.

The astir caller was Vicebio, a UK vaccine developer acquired by Sanofi for $1.6bn successful July 2025 arsenic the drugmaker tightened its vaccine pipeline. Eli Lilly spent $1.9bn to get Versanis Bio successful July 2023, portion Genmab acquired ProfoundBio for $1.8bn successful May 2024.

In total, Medicxi has created 16 caller companies since Medicxi IV successful July 2023.

Giovanni Mariggi, co-founder and spouse astatine Medicxi, told Pharmaceutical Technology that historically, the steadfast has invested astir 75% of its superior into European assets and 25% connected US assets.

For the existent fund's allocation, Mariggi said: "We expect astir 20-30% of the assets volition beryllium US-derived but we are not restricted by immoderate geographical targets oregon limits successful our superior allocation approach."

Medicxi’s co-founder and spouse Francesco De Rubertis said the firm’s “unique ties to starring planetary pharmaceutical companies and its world-class squad of cause hunters and clinicians” has helped make its longstanding success.

“The caller €500m money volition alteration Medicxi to supply the captious capital, expertise and acquisition to present transformative therapies for patients,” De Rubertis added.

Shortly aft Medicxi announced its fund, Sofinnova Partners besides unveiled its latest tranche for early-stage ventures. The Paris-headquartered steadfast closed a €650m fund, which it volition usage to substance companies addressing “urgent unmet objective needs.”

The fund’s unveiling volition beryllium invited quality to a cooling European concern scene. Despite wide biotech task backing expanding successful the 2nd fractional of 2025, European biotechs are struggling to seizure the aforesaid superior arsenic US counterparts.